Novo Nordisk A/S (NYSE:NVO) Rating Lowered to Neutral at JPMorgan Chase & Co.

Novo Nordisk A/S (NYSE:NVO) was downgraded by investment analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat reports.

NVO has been the topic of several other research reports. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. CICC Research initiated coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday. Six analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Stock Down 16.3%

Shares of NYSE:NVO opened at $39.68 on Tuesday. The stock has a market capitalization of $177.16 billion, a P/E ratio of 11.43 and a beta of 0.67. The stock’s 50-day moving average price is $53.56 and its 200-day moving average price is $53.23. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 12-month low of $39.34 and a 12-month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently made changes to their positions in NVO. Sunbelt Securities Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.5% during the fourth quarter. Sunbelt Securities Inc. now owns 21,316 shares of the company’s stock valued at $1,085,000 after purchasing an additional 323 shares during the last quarter. White Knight Strategic Wealth Advisors LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $732,000. Hamilton Wealth LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at $545,000. T. Rowe Price Investment Management Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter valued at $41,000. Finally, Compound Planning Inc. boosted its holdings in Novo Nordisk A/S by 8.2% in the fourth quarter. Compound Planning Inc. now owns 30,337 shares of the company’s stock worth $1,544,000 after acquiring an additional 2,294 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early-stage pipeline win — a China Phase 2 trial of the triple‑agonist UBT251 (GLP‑1/GIP/glucagon), developed with United Biotechnology, showed up to 19.7% mean weight loss at 24 weeks and a tolerability profile consistent with incretin therapies, which could expand Novo’s future product set beyond current semaglutide franchises. Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
• Neutral Sentiment: Wegovy/Ozempic revenue momentum remains a structural positive for the company even as sentiment sours on the pipeline; some analysts still point to strong product sales and long‑term growth from existing GLP‑1 offerings. Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
• Negative Sentiment: Major clinical setback — CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide (Zepbound/Mounjaro) in the pivotal REDEFINE‑4 head‑to‑head trial, showing weaker weight‑loss results over the trial period; this directly threatens Novo’s ability to defend/expand market share in the most valuable obesity segment. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Negative Sentiment: Quantified underperformance and market impact — reported REDEFINE‑4 numbers (e.g., ~20.2% weight loss for CagriSema vs ~23.6% for tirzepatide over 84 weeks) and the head‑to‑head loss triggered heavy selling, wiping out recent Wegovy‑era gains and pushing the stock to multi‑year lows. Novo Nordisk Shares Drop 15% After CagriSema Misses Phase 3 Goal
• Negative Sentiment: Analyst and rating pressure — at least one sell‑side analyst publicly said he’s “thrown in the towel” and firms including Deutsche Bank moved to downgrade NVO, increasing near‑term sell pressure and reducing conviction among institutional holders. Analyst says he’s thrown in the towel on Novo Nordisk after latest setback
• Negative Sentiment: Legal/investor actions — multiple law firms and investor‑representation announcements and fraud‑investigation notices have appeared, which can prolong uncertainty and pressure sentiment even if no formal enforcement action is taken. NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.